Pfizer lines up access to 'doggybone DNA' in manufacturing of mRNA vaccines, gene therapies and more
As Pfizer builds a whole franchise of genetic products on the cornerstone of its mRNA Covid-19 vaccine, it’s testing out a new way to manufacture them.
Touchlight, which has been netting deals in the ever-expanding and competitive DNA manufacturing space, has inked a non-exclusive patent license agreement with Pfizer. The deal gives Pfizer rights to Touchlight’s enzymatic DNA, called doggybone DNA, or dbDNA, to manufacture and commercialize mRNA-based vaccines and therapeutics as well as DNA vaccines and gene therapies.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.